Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vomiting 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Postoperative Nausea and Vomiting 1Papillomavirus Infections 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Gynecologic Cancer 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma in Situ 1Carcinoma 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Bevacizumab 69atezolizumab 54lenvatinib 42durvalumab 42Nivolumab 38pembrolizumab 35tremelimumab 28Magnetic Resonance Spectroscopy 21Specimen Handling 19tislelizumab 18sintilimab 17Ipilimumab 15Sorafenib 14regorafenib 13cabozantinib 13Radiosurgery 13Radiotherapy 12apatinib 11Blood Specimen Collection 11Immunoglobulin G 10camrelizumab 9Immune Checkpoint Inhibitors 9Disulfides 9X-Rays 8Cyclophosphamide 8donafenib 7Oxaliplatin 7Immunotherapy 7Folfox protocol 7Fluorouracil 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Ondansetron × 1 year × Clear all
NCT07381634 2026-03-11

The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
134 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡